A surprising fact about the much-predicted Darwinian attrition that has hit the biotech industry over the past 18 months is that it has impacted more than just the weakest. Some of the industry's ...
Metabasis Therapeutics Announces CS-917 Phase 2b Clinical Trial Results and Reports on Status of Pradefovir SAN DIEGO -- Jul 17, 2007 - Metabasis Therapeutics, Inc., a biopharmaceutical company ...
SAN DIEGO, Aug 07, 2008 - Metabasis Therapeutics announced today that it has entered into a two-year research collaboration agreement with Roche to apply Metabasis' HepDirect(R) liver-targeting ...
Metabasis Therapeutics, Inc. has announced an extension to the sponsored research term under its collaboration with Merck & Co., Inc. for an additional year, through June 2009. The two companies will ...
Amendment comes as Metabasis strives to keep its head above water. Struggling Metabasis Therapeutics has opted to receive a $6 million one-time fee from Merck & Co. in lieu of the $54 million it could ...
Both Metabasis Therapeutics and Ligand Pharmaceuticals have long histories in San Diego. The faltering biotechnology company Metabasis Therapeutics said yesterday that it has agreed to a takeover by ...
Metabasis retains all development and marketing rights to MB07803. The first drug candidate in this class, CS-917, also discovered by Metabasis, is being developed in collaboration with Sankyo Co., ...
Ligand pledges at least $8 million toward Metabasis’ metabolic and liver disease programs. Ligand Pharmaceuticals is to acquire Metabasis Therapeutics for about $1.8 million net in cash plus four ...
That first sound was developmental stage drug maker Metabasis (NASDAQ:MBRX) hitting the floor. It recently heard from its partner, Daiichi Sankyo, that its diabetes drug, CS-917, had failed to show an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results